The preclinical company pulled off a giant flotation, and though its stock has since slumped it now has several years’ cash to play with.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
And four other potential targets that could make sense for the beleaguered group.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.